|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Bioseeker, Feb 2008, Pages: 540
This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of lung cancer and melanoma. This extensive 540+ pages report compiles and analyzes Apoptosis, the type of death about whose genetically controlled pathways we know the most, and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer
The author has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications.
To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.
The report by the numbers
- A hundred different tables. Includes more than 1,500 active links to related resources on the Internet
- 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
- 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
- 90 Unique drug target combinations of apoptopic drugs
- 452 protein-protein interactions among apoptopic drug targets
- Extensive pathway analysis of drug targets
The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data.
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analyzed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine).
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis
Cancer Drug Resistance
Drug Delivery in Cancer - Technologies, Markets and Companies
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis
Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
Targeted Therapeutics in Non-Small Cell Lung Cancer
Currently Druggable in Melanoma: A Drug Target Competitive Analysis
Prostate and Breast Cancer- New Treatments & Developmental Progress
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma
|
|
|
|
